Predictions
Pacific Biosciences of California Inc.
Start price
Target price
Perf. (%)
€6.70
16.09.20
16.09.20
€8.00
21.09.20
21.09.20
5.97%
21.09.20
21.09.20
Could be worthwhile Investment >10% per year
Cutera Inc.
Start price
Target price
Perf. (%)
€16.40
16.09.20
16.09.20
€18.00
21.09.20
21.09.20
0.00%
21.09.20
21.09.20
Could be very worthwhile Investment >20% year
CHF Solutions Inc
Start price
Target price
Perf. (%)
-
16.09.20
16.09.20
€0.000
21.09.20
21.09.20
-
21.09.20
21.09.20
Could be very worthwhile Investment >20% year
GoldMining Inc
Start price
Target price
Perf. (%)
€2.25
16.09.20
16.09.20
€3.00
04.11.21
04.11.21
-49.80%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
Südzucker AG
Start price
Target price
Perf. (%)
€17.09
16.09.20
16.09.20
€40.00
04.11.21
04.11.21
-18.67%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
Revenue growth > 30% per year expected
EBIT growth >5% per year expected
Rising EBIT margin expected
Drone Delivery Canada Corp.
Start price
Target price
Perf. (%)
€0.44
15.09.20
15.09.20
-
04.11.21
04.11.21
26.70%
01.12.20
01.12.20
Very Future proof/growth oriented business model
Innovative
Some uniques
Higher risks for its business
Copart Inc.
Start price
Target price
Perf. (%)
€89.00
15.09.20
15.09.20
-
04.11.21
04.11.21
8.99%
27.11.20
27.11.20
Capable Management
Market Leader or Top 3
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Kelly Services Inc. A
Start price
Target price
Perf. (%)
€14.00
15.09.20
15.09.20
-
04.11.21
04.11.21
32.14%
15.07.21
15.07.21
Risky Investment
Somfy S.A.
Start price
Target price
Perf. (%)
€114.00
15.09.20
15.09.20
€150.00
04.11.21
04.11.21
50.53%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
Cassava Sciences Inc.
Start price
Target price
Perf. (%)
€5.92
15.09.20
15.09.20
€3.00
30.09.20
30.09.20
72.89%
30.09.20
30.09.20
Could be worthwhile Investment >10% per year
BioNTech SE ADR
Start price
Target price
Perf. (%)
€57.26
14.09.20
14.09.20
€78.00
16.10.20
16.10.20
39.19%
16.10.20
16.10.20
Could be very worthwhile Investment >20% year
Hewlett Packard Enterprise Co
Start price
Target price
Perf. (%)
€7.96
14.09.20
14.09.20
-
04.11.21
04.11.21
11.01%
19.11.20
19.11.20
Top 10 in its market
Well known brand
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Apple Inc.
Start price
Target price
Perf. (%)
€95.98
14.09.20
14.09.20
-
04.11.21
04.11.21
37.03%
05.11.21
05.11.21
Could be very worthwhile Investment >20% year
PIMCO Dynamic Credit Income Fund
Start price
Target price
Perf. (%)
€20.32
13.09.20
13.09.20
€22.97
24.10.24
24.10.24
-14.99%
13.06.22
13.06.22
Paragon AG
Start price
Target price
Perf. (%)
€9.89
12.09.20
12.09.20
-
04.11.21
04.11.21
-4.95%
16.11.20
16.11.20
Capable Management
Revenue growth >5% per year expected
MTU Aero Engines AG
Start price
Target price
Perf. (%)
€157.65
12.09.20
12.09.20
-
04.11.21
04.11.21
23.22%
14.11.20
14.11.20
Good rating
positive Cash Flow expected
Revenue growth >5% per year expected
Normal challenges to pay loans and raise capital
Verisign Inc.
Start price
Target price
Perf. (%)
€169.72
11.09.20
11.09.20
-
04.11.21
04.11.21
-1.60%
25.11.20
25.11.20
Probably not worthwhile Investment
Revenue decline/stagnation expected
Very low/no dividend yield expected
Bolloré S.A.
Start price
Target price
Perf. (%)
€3.24
11.09.20
11.09.20
€4.50
04.11.21
04.11.21
56.44%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
Novozymes A/S B
Start price
Target price
Perf. (%)
€55.52
11.09.20
11.09.20
€63.00
04.11.21
04.11.21
18.70%
05.11.21
05.11.21
Market Leader or Top 3
Higher EBIT margin than peer group
positive Cash Flow expected
Revenue decline/stagnation expected
Samsung SDI Co. Ltd. GDR
Start price
Target price
Perf. (%)
€77.40
11.09.20
11.09.20
-
04.11.21
04.11.21
32.43%
22.11.20
22.11.20
Future proof or reliable business model
Market Leader or Top 3
Innovative
Well known brand
Satsuma Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€4.30
11.09.20
11.09.20
€2.00
04.11.21
04.11.21
16.74%
17.06.21
17.06.21
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group